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Abstract
Objectives: Medical compression therapy is used for non-invasive treatment of venous and lymphatic diseases. Medical
compression therapy-associated adverse events and contraindications have been reported, although some contraindi-
cations are theoretically based. This consensus statement provides recommendations on medical compression therapy
risks and contraindications.
Methods: A systematic literature search of medical compression therapy publications reporting adverse events up until
November 2017 was performed. A consensus panel comprising 15 international experts critically reviewed the pub-
lications and formulated the recommendations.
Results: Sixty-two publications reporting medical compression therapy adverse events were identified. The consensus
panel issued 21 recommendations on medical compression therapy contraindications and adverse event risk mitigation,
in addition to reviewing medical compression therapy use in borderline indications. The most frequently reported non-
severe medical compression therapy-associated adverse events included skin irritation, discomfort and pain. Very rare
but severe adverse events, including soft tissue and nerve injury, were also identified.
Conclusion: This consensus statement summarises published medical compression therapy-associated adverse events
and contraindications, and provides guidance on medical compression therapy. Severe medical compression therapy-
associated adverse events are very rarely encountered if compression is used correctly and contraindications are
considered.
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Medical compression (MC) devices, including MC
stockings (MCS), compression bandages (CB), adjust-
able compression wraps (ACW) and thromboprophy-
lactic stockings (TPS) are basic management options
for the non-invasive treatment of venous and lymphatic
diseases. A wide range of side effects associated with
their use and contraindications have been reported in
the literature. These are based mostly on case reports
and consensus documents, but some are based solely
on theoretical concerns. The aim of this consensus was
to review the available literature, to undertake a critical
appraisal of reported side effects, and to provide rec-
ommendations on contraindications and risks of MC
treatment. In this paper, although intermittent pneu-
matic compression (IPC) is an important component
of compression therapy, we report on side effects and
contraindications of IPC only when they differ from
those of other forms of compression therapy.
Methods
Consensus panel
The consensus panel contributing to the development
of this article comprised 15 international experts expe-
rienced in compression therapy, representing different
medical disciplines (angiology, cardiology, dermatolo-
gy and vascular surgery). The consensus group is
chaired by the primary author, Eberhard Rabe, and
comprises a core group (Christopher R Lattimer,
Mark H Meissner, Nick Morrison, Eberhard Rabe,
and Hugo Partsch) and an extended group, whose
members were proposed by the group’s Chair and its
co-Chair, Hugo Partsch. The responsibility of the
experts, supported by a secretary, Sylvain Gaillard,
was to perform and refine the literature searches and
to use personal records and knowledge to select and
draft the initial recommendations. These were used as
a framework for discussion prior to writing the article.
Study design
A systematic literature search was performed for
articles, guidelines and treatment recommendations
published up to November 2017 which reported
adverse events related to MC treatment. The primary
search terms used were: ‘compression bandages’,
‘medical compression stockings’, ‘graduated elastic
compression’, ‘adjustable compression’, ‘thrombopro-
phylactic stockings’ and ‘TPS’. These were cross-
matched with: ‘complications’, ‘adverse events’,
‘contraindications’, ‘side effects’ and ‘risks’. The
search used the online citation search engine
PubMed. The search results are summarised in
Figure 1. An additional search performed up to
December 2019 did not identify any new publications
on the contraindications for compression based on
original data.
Risks and complications for compression therapy
reported in literature
This paper reviews common risks and complications of
compression therapy reported in literature (Table 1),
including skin irritation and pruritus, rare complica-
tions such as superficial venous thrombophlebitis at
the upper stocking border, decompensation of heart
failure or spread of bacterial and/or fungal infection,
and exceptional but potentially devastating complica-
tions such as nerve damage, venous thromboembolism,
arterial thrombosis and skin or limb necrosis. All of the
more severe complications are very rare and occur in
predisposed patients or during improper use of com-
pression therapy. Therefore, every patient receiving
compression therapy should be screened for conditions
that increase the risk of complications, and every com-
pression device should be checked for appropriate fit
and application. The use of compression therapy must
be considered carefully in the presence of such condi-
tions, and contraindications must be considered. Many
of the reported risks are similar in MCS and CB but
there are also some considerable differences. For exam-
ple, in a patient with severe peripheral arterial occlusive
disease (PAOD) with an ankle pressure of 60mmHg
for whom a contraindication for MCS exists, well-
padded inelastic CB applied with low pressure may
be appropriate even with an ankle pressure of
50mmHg.1
Recommendation 1. We recommend that every patient
receiving compression therapy should be screened for
conditions that increase the risk of complications, and
every compression device should be checked for appro-
priate fit and application. Contraindications for compres-
sion treatment must be considered to limit the risk of side
effects.
Skin irritation
Low-severity skin problems, including itching, feeling
cold or warm and dry skin, are frequently associated
with compression therapy.2,3 The higher incidence of
itching and dryness reported with MCS when com-
pared with TPS may be partially explained by the
skin of MCS patients already being compromised due
to venous congestion. Skin irritation may be mistaken
for allergic reactions, but usually they are self-limiting,
can be controlled without interruption of the compres-
sion treatment and may be prevented through adequate
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skin care. A considerable number of potentially
treatment-related adverse events, including irritant
inflammatory skin reactions below four-layer bandage
systems and short-stretch bandaging, has been
described in a Canadian trial.4 Delayed bandage
changes are contributory, as these prolong contact
with irritant topical applications on pre-sensitised
skin of venous disease patients. Tension-induced skin
stress is a frequent experts’ observation occurring in
patients after a well applied bandage or measured
stocking has been removed. It is manifest as circumfer-
ential red lines or a patch of redness, typically over
fulcrum areas, where the fabric of the material rubs
against the skin. Whilst not reported as a complication
and reversible, it may represent the physical evidence of
why compression devices may cause discomfort or
irritation.
Recommendation 2. We recommend using adequate skin
care to prevent skin irritation in patients with sensitive
skin.
Allergic skin reactions
In most cases, inflammatory skin reactions are caused
by skin desiccation and skin irritations due to an occlu-
sive barrier effect of the compression material. True
allergic skin reactions to compression materials are
rare, as allergenic components are usually avoided in
Table 1. Summary of reported adverse events.
Reported adverse events Incidence
Non-severe
Skin irritation4,5,20,21,23,25–31,36,37 Common
Allergic skin reaction5,6 Very rare
Discomfort and pain7 Common
Forefoot oedema and lymphoedemaa Rare
Bacterial and fungal infection4,9,10 Very rare
Severe
Soft tissue damage or necrosis20–30,34–37,62 Very rare
Nerve damage31–37 Very rare
Arterial impairment24,77 Very rare
Venous thromboembolism43 Very rare
Cardiac decompensation47 Very rare
Frequency grouping: very common (1/10), common (1/100 to <1/10),
uncommon (1/1000 to < 1/100), rare (1/10,000 to <1/1000), very
rare (<1/10,000), frequency not known (cannot be estimated from the
available data).89
aBased on experts’ experience.
Source: reproduced with permission from European Commission, 2009.89
Figure 1. Preferred Reporting Items for Systematic reviews and Meta-Analyses flow diagram of relevant literature identified.
RCT: randomised controlled trial.
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actual MC products, but have been noted following the
use of rubber-based products.5 Most current compres-
sion products no longer contain natural rubber or
latex. For the same reason, type IV sensitisation to
sulphur-containing catalysers of vulcanisation of natu-
ral rubber is of almost no relevance. Sensitisation to
paraphenylenediamine, the basic component of black
and dark blue dyes, may cause allergic contact derma-
titis to compression stockings of dark colours but in
many countries, paraphenylenediamine-containing col-
ours are no longer used in clothing materials.6
Recommendation 3. To prevent allergic skin reactions due
to compression devices, we suggest avoiding potentially
allergenic substances and dyes in compression materials.
Discomfort and pain
The feeling that a compression device, MCS, TPS or
CB, is ‘too tight’ is often reported by the patient on first
application and may influence compliance. It may take
several days before patients get used to wearing com-
pression. Compression discomfort is experienced usu-
ally around the ankle or foot. Discomfort or pain
below compression may be due to the new experience
of ‘pressure on the leg’ but may also be due to incorrect
sizing, bandaging technique or indication for the select-
ed pressure level, and allowing patients to select their
stocking from an array of choices is an option for
improving patient compliance.7
Recommendation 4. In patients with discomfort and/or
pain below compression garments, we recommend check-
ing the correct indication, pressure level, material, fitting
or bandage techniques as well as the correct donning and
doffing.
Forefoot oedema and lymphoedema
Classical compression devices apply low or no pressure
to the flat dorsum of the forefoot and toes. According
to experts’ experience in susceptible patients, in immo-
bile patients and, in particular, in lymphoedema, this
may lead to increased swelling in the forefoot and toe
area, with a theoretically increased risk of interdigital
fungal infection. Prevention and treatment consist of
including the forefoot and the toes in the compression
with special additional compression garments. In addi-
tion, healthcare professionals (e.g. wound care nurses)
should be trained in applying these techniques.
Several cases of genital lymphoedema development
or worsening after IPC treatment have been reported in
a single retrospective study.8 Possibly related to
improvements in IPC systems, more recent studies
investigating the safety of IPC treatment have not
reported cases of IPC-related genital lymphoedema.
Compression of the lower leg alone may cause
increased swelling of the knee region. Based on the
experts’ experience, the length of compression gar-
ments should be adapted to the region of pathological
findings.
Recommendation 5. In patients with, or in those develop-
ing, forefoot or toe oedema when wearing compression,
we suggest considering forefoot and toe bandaging or
forefoot and toe compression pieces in addition to leg
compression with a foot piece.
Bacterial and fungal infections
In many conditions treated with compression devices,
such as venous ulcers and lymphoedema, concomitant
bacterial and fungal colonisation or infection may be
present. The occlusive barrier effect of compression
devices in the toe area may add to the risk of infection,9
which may be mitigated by toe-free compression.
Folliculitis of the skin associated with IPC has also
been reported.10
Bacterial colonisation of the skin and chronic
venous leg ulcers (VLU) is common and, in the absence
of clinical signs of systemic infections, is often treated
with topical antiseptics, dedicated dressings and necrot-
ic tissue debridement. Current guidelines suggest no
local or systemic antibiotic treatment for bacterial col-
onisation in cases where no systemic infection is evi-
dent.11,12 The evidence strongly supports the use of MC
for VLU treatment in patients with local bacterial
wound colonisation. There is no evidence that com-
pression may worsen bacterial colonisation or infec-
tion. An application of compression together with
local wound treatment facilitates and accelerates
wound healing in this clinical setting.11,12 Studies
have shown that restricting the use of MC in VLU
treatment leads to prolonged ulcer healing.13 In certain
cases of VLU treatment, local bacterial colonisation or
infection may worsen below MC despite the use of
appropriate local therapy.
According to experts’ experience, such worsening is
usually multifactorial and, in most cases, related to
changes in wound condition and bacterial type.
In the Canadian Bandaging Trial, the occurrence of
infection was treated as an adverse event.4 However,
this interpretation is controversial and comparative
data with and without compression are missing. In
other studies, the use of compression is associated
with shortened ulcer healing times, and local bacterial
loads have not been found to affect duration of
treatment.11,12,14
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Current evidence is lacking for the occurrence of
infectious complications of previously uninfected skin
after MCS use. In isolated cases, pre-existing bacterial
colonisation may exploit changes in the local environ-
ment triggered by compression garment materials or by
skin injuries caused by folding of ill-fitting MCS.5
Erosive pustular dermatosis (EPD) has been
described as a rare, mostly non-infectious condition
in association with venous insufficiency and atrophy
of the skin of the lower leg during long-term permanent
four-layer bandaging. Intermittent compression regi-
mens improved EPD compared with the permanent
application of a four-layer bandage system producing
sustained compression in patients unresponsive to anti-
biotics for confirmed bacterial infection of the skin of
the lower leg.15
Possible fungal colonisation has also been described
in some leg ulcer patients treated with MCS infused
with skin care ointment, but it is not clear if this colo-
nisation was due to the ointment or the compression.9
Compression materials may also exert antiseptic
effects. Zinc oxide compression dressing was compared
with standard wound care for the treatment of sutured
excisions on the legs and found to promote superior
healing compared with standard wound care.16
Incorporation of antimicrobial substances in MCS
products has led to the development of antimicrobial
compression garments containing nanoparticles or
fibres made of silver.17
There is no evidence that compression principally
increases the risk of infection. To the contrary, com-
pression may facilitate healing in conditions such as
erysipelas in lymphoedema or in VLU, despite bacterial
colonisation. However, in rare cases and under special
conditions (e.g. lateral compression of the toes with
interdigital maceration, long-lasting occlusive barrier
effects beneath four-layer bandages), local compression
effects may foster microbiological colonisation.
Recommendation 6. In patients with bacterial or fungal
infection beneath the compression device, we recommend
considering treatment with topical antiseptics or topical
anti-microbiological medication. In patients with system-
ic symptoms (fever, chills), erysipelas or cellulitis, we
recommend that systemic treatment should be given. In
other cases of systemic symptoms and severe local wound
and tissue infection, the decision on the further treat-
ment, including also MC, should be individualised on
the basis of the local and general patient condition
evaluation.
Recommendation 7. If the compression application or
material is suspected to contribute to the infection (e.g.
lateral pressure on toes with interdigital maceration), we
suggest a modification of compression.
Mechanical tissue and nerve damage
Compression exerted by CB, TPS, adjustable compres-
sion garments and MCS is mediated through tension.
As a consequence of the Law of Laplace, areas on the
legs with smaller radius and bony or tendinous prom-
inences are subject to higher local pressure than flat
areas made up of predominantly softer tissue.18
Higher local pressure may result in pressure necrosis,
tissue ischaemia or nerve damage, and is a particular
problem in aged, malnourished, or sun-damaged skin
with little supporting subcutaneous fat.
A reduced ankle-brachial pressure index (ABPI) is
contributory to the risk of tissue damage by compres-
sion although it does not measure skin perfusion direct-
ly.19 Areas affected include the tibialis anterior tendon,
the Achilles tendon, the anterior border of the tibia, the
malleoli and the head of the fibula. Prevention involves
reducing the inappropriate high pressure by decreasing
the locally elevated pressure through appropriately
placed soft padding material, using lower pressure
levels, taking appropriate circumference measurements
so that the compression devices fit properly and using
flat-knitted material where round-knitted stockings are
not applicable due to high calf/ankle circumference
ratios.
Failure to maintain appropriate position on the leg
with TPS, MCS or CB, which may lead to strangula-
tion or inappropriate high local pressure values or con-
tinuous high pressure values, has been reported in
association with tissue damage, and may also lead to
arterial compression and necrosis. An additional risk
factor for tissue necrosis is severe PAOD or severe
microangiopathy, which are common in patients with
diabetes.
Recommendation 8. We suggest considering that, accord-
ing to the Law of Laplace, the local pressure below the
compression material may be higher than expected at
bony and tendinous prominences such as above ankles,
the tibia, the fibular head or above tendons such as the
Achilles tendon, and to check those locations for skin
lesions due to pressure.
Recommendation 9. To prevent tissue damage or necrosis
and nerve damage in regions with a small radius, we
suggest protecting these regions (tendons, nerves and
bones) from inappropriate high pressure, particularly in
patients with sensitive skin, by:
• Decreasing the local pressure by inserting soft padding
material
• Using low overall pressure
• Taking appropriate circumference measurements so
that the compression devices fit properly
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Soft tissue damage or necrosis
Single cases of skin damage and/or skin necrosis due to
inappropriate use of TPS in patients with or without
pre-existing PAOD have been reported.20,21
Two cases of skin breaks located at the popliteal
fossa and the heel, respectively, were related to the
use of two inadequately superimposed MCS, which
delivered a combined, sustained (day and night) pres-
sure of 40mmHg at the ankle over a prolonged period
of time.22 Pressure ulcers in the popliteal fossa associ-
ated with the use of TPS have also been reported.23
A survey among general surgeons in Scotland found
that 11% of the respondent surgeons had observed
development of tissue necrosis secondary to the use
of graduated MCS in their patients.24 In the CLOT I
study, which investigated the benefit of TPS in stroke
patients, skin breaks, ulcers, blisters, skin necrosis and
lower limb amputations were significantly more
common in patients treated with TPS.25 Pressure-
induced skin lesions, as described above, may be
assumed to be more frequently related to the use of
high-pressure MC bandages. Distal foot ulcers in
patients with normal arterial circulation have been
described as a complication of firmly applied MC ban-
dages.26 Tissue damage has also been described by
inappropriate use of or malfunctioning IPC devi-
ces.27–30
Recommendation 10. We suggest specific precaution
(padding, special care of fit, low pressure), and close
controls at the initial stages of compression therapy in
patients with polyneuropathy and elderly patients with
frail, atrophic skin (dermatoporosis).
Nerve damage
Peripheral nerve damage with numbness or palsy fol-
lowing compression treatment has been reported fol-
lowing compression bandaging, IPC and after use of
MCS or TPS.31–37 The common peroneal (fibular)
nerve at the fibular head was the most frequently affect-
ed injury site, and the typical presentation of common
peroneal nerve palsy included acute, complete or par-
tial foot drop along with associated numbness in the
affected foot or leg.31–33,35–37
In most cases, poorly fitted MCS or TPS and inad-
equate compression techniques with strangulation
resulted in persistent, high focal pressure to a superfi-
cial nerve. Insufficient protection of a superficial nerve
by padding below the compression in regions at risk
was also reported. Symptoms of nerve damage were
generally noted within a few hours of increased com-
pression, and significant clinical improvement occurred
in approximately three weeks to six months, depending
on the extent of nerve damage.
In general, the factors reported as causes of
pressure-induced nerve damage are similar to the pro-
cesses causing soft tissue damage:
• Incorrectly sized TPS or MCS,36,37 especially when
combined with intraoperative use of IPC devices
that provide additional focal compression to a vul-
nerable area34,37
• Slipping and/or rolling of TPS or MCS resulting in
increased persistent local compression34
• Sensory loss, especially in patients with diabetic neu-
ropathy or following anaesthesia, as a potential
cause of non-perception of local pressure damage35
• Hereditary disposition to developing pressure
palsies37
The risk depends on the duration and pressure of the
compression effect as well as patient-specific conditions
such as cachexia, anatomic variations and patients with
a habit of leg crossing.31,36
Recommendations in the literature for the preven-
tion of nerve palsy include:
• Guidelines on correct sizing and application of TPS
or MCS should be followed34,36,37
• Patients should be routinely questioned about the
comfort of their bandaging and symptoms sugges-
tive of neurological disturbance31
• The anatomy of the extremities including the nerves
should be taught to those applying compression
bandaging31
• Routine surveillance is required for skin damage and
reassessment to ensure correct application of TPS,
MCS or bandaging,31,36,37 especially with distant
operative sites and in patients with one or more
related risk factors34,36,37
• Periodic neurological assessment is needed in
patients on long-term chronic compression
therapy31
• Above-knee TPS or MCS should be used36,37
• Patients should be educated about recognising
symptoms suggestive of neurological disturbance
and minimisation of leg-crossing habits31
Recommendation 11. We suggest considering that
pressure-induced nerve damage may occur at specific
points of the leg (e.g. fibular head) mainly in cases
with excessive local compression pressure, e.g. due to
ill-fitting MCS, TPS or CB. Numbness and nerve palsy
may occur. We suggest preventing high or continuous
local pressure in regions with a risk of nerve compression
as well as correct sizing and application of compression.
Patients at higher risk for nerve damage (e.g. patients
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with diabetes, patients with neuropathy) should be
treated with special caution to prevent nerve damage.
PAOD in compression treatment
PAOD with low ankle pressure and low ABPI may
interfere with compression treatment and increase the
risk of soft tissue damage and necrosis due to insuffi-
cient arterial nutrition underneath the compression
area. This may happen more often in regions with ele-
vated local pressure beneath compression devices such
as ankles, tendons or in the foot (see the section ‘Soft
tissue damage or necrosis’). To avoid skin injury by
compression in severe PAOD, ankle pressure and
ABPI or toe pressure should be measured and calculat-
ed before compression treatment is initiated.
Recommendation 12. We recommend checking the arteri-
al circulation status before any kind of compression ther-
apy is initiated. If foot pulse and/or ankle pulse is weak
or not palpable, ABPI should be measured and calculated
prior to initiating MC therapy.
In severe PAOD, sustained compression is contra-
indicated if the systolic ankle pressure is <60mmHg or
the toe pressure is <30mmHg. This is a clear contra-
indication against compression therapy with MCS. In
CB, the applied pressure and the elasticity of the mate-
rial are important. Inelastic material may provide very
low resting pressure and pressure peaks during walking
only, which may be well tolerated and even increase
arterial flow as oedema subsides.
Recommendation 13. Severe PAOD (systolic ankle pres-
sure <60mmHg, toe pressure <30mmHg) is a contra-
indication against compression therapy with MCS. In
CB, the applied pressure and the elasticity of the material
are important. This contraindication does not apply to
IPC and to patients with non-critical leg ischaemia
treated with inelastic material applied with low resting
pressure.
Recommendation 14. In every patient with impaired per-
fusion of the lower limb (ABI <0.9), the clinical effect of
the MCS on leg blood supply should be carefully moni-
tored. If the situation is not recognised, there is a possi-
bility of developing non-healing skin breaks even under
low pressure MCS.
Compression after arterial bypass surgery or stenting
Most surgical anatomic bypasses for PAOD are located
deep below the muscular fascia, and it is unlikely that
compression will adversely affect arterial inflow.
However, in extra-anatomical bypasses, the anastomo-
sis and the bypass itself may be very superficial, and
thus compression of the epifascial bypass conduit
should be avoided. Special care should be also taken
in patients with in situ venous femoro-popliteal (espe-
cially distal popliteal) or tibial bypasses or in patients
with very distal lower-leg anastomoses, which are usu-
ally located very superficially in the lower leg tissue – in
these cases, standard compression should be avoided.
No published data of damage by compression treat-
ment in this patient group have been identified.
Recommendation 15. After bypass surgery with improved
peripheral arterial pressures, MC treatment may be per-
formed if there is no direct compression effect on the
bypass itself. We suggest avoiding the compression of
epifascial bypass conduits.
As for all patients with chronic leg ischaemia, the
recommendations regarding the use of MC treatment
should be followed (see recommendations 12–14).
Venous thromboembolism
Compression is not a contraindication in venous
thromboembolic conditions but rather helps to reduce
pain and oedema in deep vein thrombosis (DVT)
immediately, allowing for comfortable ambulation.38–
41 Thromboembolic complications due to MC are rare,
most of them are without clinical symptoms.42
MCS and TPS may cause superficial venous throm-
bosis (SVT) in patients with varicose veins, primarily in
regions where they could exert a tourniquet effect. In a
study of airline passengers, elastic compression stock-
ings during long-haul air travel were associated with a
reduction in symptomless DVT, but 3.8% of patients
developed SVT in varicose veins in the knee region,
which were compressed by the upper edge of the
stocking.43
Recommendation 16. Because of a tourniquet effect,
improper compression can cause local SVT, especially
in combination with prolonged sitting (long-haul flights).
To prevent thromboembolic complications, we recom-
mend avoiding a tourniquet effect and strangulation by
inappropriate application of MCS, TPS and bandages.
Cardiac insufficiency
According to national and international guidelines,
decompensated cardiac insufficiency is considered to
be contraindicative for phlebological and lymphologi-
cal compression bandaging, MCS and manual lym-
phatic drainage.44–46
A recent review of 20 international guidelines and
consensus papers published between 2009 and 2016 on
venous ulcer concluded that only pulmonary oedema
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should be regarded as a contraindication for compres-
sion treatment.47
The results of studies on the redistribution of region-
al blood volumes by applying compression to the legs
of patients in supine position with the help of inflatable
rubber boots indicated a reduction in blood volume in
the legs and an increased blood volume in the organs of
the thorax, abdomen and the liver.48 Similar blood-
volume shifts in the legs were identified when classes
I and II MCS (18–32mmHg) were worn on the lower
legs.49 Due to the elastic properties of the lower vena
cava and the large number of visceral veins, only a
fraction of the blood displaced from the legs reaches
the right atrium. The volume overload caused by a
change in the cardiac output will be compensated by
the heart rate. In structural cardiac disease, changes in
the behaviour and regulation of the myocardium have
been observed.50,51
In patients with long-standing severe congestive
heart failure, short-term increases in cardiac return
may increase right heart pressures but do not appear
to influence left heart haemodynamic indices.51,52 An
increased volume in the right atrium produces a local
rise in pressure as well as an increased expression of
natriuretic peptides (NPs) triggered by a strain on the
heart wall as a result of over-distension.53 In a compar-
ative study of patients with chronic venous
insufficiency (CVI) with or without cardiac insufficien-
cy (New York Heart Association Functional
Classification II (NYHA II))54 who wore class II
MCS (25–32mmHg), a significant rise in NPs due to
MCS was reported in the heart disease group, who
already had increased baseline values.55 This tempo-
rary rise in NPs was not accompanied by haemody-
namic changes, and it was concluded that
compression therapy using compression class II MCS
on the lower leg does not constitute a risk to patients
with NYHA II cardiac insufficiency.55
A similar conclusion was reached in a study where
right heart catheterisation was used to investigate
haemodynamic changes following the application of
multilayer bandages on patients with NYHA III and
IV-grade cardiac insufficiency in a cardiac intensive
care unit. Initial increases in right atrial and ventricular
pressure were observed after application of the ban-
dages, followed by a return to baseline values without
any long-term clinical impairment.56
An evaluation of the impact of locally applied
manual lymphatic drainage on patients with NYHA
III and IV-grade cardiac insufficiency concluded that,
despite a highly significant reduction in the circumfer-
ence of the treated extremities, there were no significant
changes in haemodynamic parameters other than heart
rate, and that using locally applied manual lymphatic
drainage in the legs as a decongestive therapy in
patients with NYHA III and IV-grade cardiac insuffi-
ciency does not constitute a contraindication.57
No pulmonary impairment, observed as pulmonary
oedema, was triggered in any of the examined test sub-
jects in a study where CB were applied to patients with
decompensated cardiac insufficiency to prevent fainting
as a consequence of seating-induced postural hypoten-
sion, despite an increase in blood pressure.58
Currently no studies have evaluated the significance
of refractory or unstable hypertension. However, stud-
ies and consistent observations of volume displacement
due to immersion have indicated that compression can
contribute to pulmonary oedema in such cases.59,60
Overall, key points to note regarding case reports
and experimental studies on cardiac insufficiency and
compression therapy include:
1. Cardiac insufficiency in itself does not constitute a
contraindication for compression therapy.
2. In the disease stages NYHA I and NYHA II, appro-
priate compression is possible.
3. In the disease stages NYHA III and IV, careful use
of compression therapy is possible to a limited
extent if there is a strict indication, clinical and hae-
modynamic monitoring.
In patients with oedema and cardiac insufficiency, it
is recommended to start compression therapy with
reduced pressure on one lower leg and slowly progress
to stronger pressure applied on both legs.
Recommendation 17. We recommend against applying
compression in severe cases of cardiac insufficiency
(NYHA IV). We also suggest against routine applica-
tion of MCS in NYHA III cases. When needed, careful
use of compression therapy in this patient group may be
considered if there is a strict indication, with clinical and
haemodynamic monitoring. In less severe cases, cautious
increase of compression pressure only leads to very short
phases of increased cardiac load and may lead to a sub-
stantial reduction of peripheral oedema.
Borderline indications and previously
reported contraindications
Compression may have positive effects in clinical sit-
uations, in which compression use was previously con-
sidered to be contraindicated, herein referred to as
‘borderline indications’.
A clinical case review noted that layered compres-
sion therapy is an effective and safe treatment in
patients with DVT and SVT, oedema, venous ulcera-
tion or pre-ulceration and diabetes with adequate arte-
rial circulation.61 Reduced compression can be helpful
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in patients with diabetes, arterial compromise, oedema
and venous ulceration or pre-ulceration. Conversely,
excessive compression may be disastrous, as shown in
a case report of a 76-year-old, overweight patient with
diabetes who, following treatment with 40–60mmHg
MCS due to leg ulcers and oedema, developed a deep
necrosis over the dorsal tendon of the ankle joint, pre-
sumably due to rolling of the stocking over the tissue
defect.62
Deep and superficial vein thrombosis
The avoidance of compression in patients with estab-
lished DVT or SVT appears to be based only on theo-
retical grounds, as compression might promote the
dislodgement of clots and cause pulmonary embolism
(PE). There are no data supportive of this theory.
Routine lung scans in patients with DVT not treated
with compression treatment have demonstrated that
PE is found in more than 50% of patients with DVT,
thus demonstrating that DVT is a thromboembolic dis-
ease. Most of these pulmonary emboli are clinically
silent, with the incidence of PE depending on the loca-
tion of the thrombus.42
In a cohort of patients with acute DVT treated with
either low-molecular-weight heparin (LMWH) plus
compression and walking or LMWH plus bed rest,
new PEs (majority asymptomatic) occurred in <7.4%
of patients in both groups.42 Three randomised con-
trolled trials (RCTs) also demonstrated that early
mobilisation does not increase the frequency of PE
compared with bed rest in patients with DVT treated
with anticoagulation.39,63,64 The situation is similar in
patients with SVT, as approximately 34% of patients
with acute-phase SVT have predominantly asymptom-
atic PE.65,66
In an RCT of patients with isolated SVT, patients
treated with LMWH plus compression stockings dem-
onstrated faster thrombus regression and no increased
risk of PE compared with LMWH alone, but did not
show any improvement of pain compared with no
compression.67
Following a European tradition, compression in
acute SVT or DVT belongs to the standard treatment
of these diseases, because firm compression leads to an
immediate reduction of pain and swelling in patients
with acute DVT.39–41,67–69 There are no data suggesting
that compression of veins filled with clots may lead to
an increased risk of PE or post-thrombotic syndrome
(PTS).39,41,63,64,70,71
Recommendation 18. We recommend considering that, in
contrast to previous concepts, compression is not contra-
indicated in acute thrombotic events, but results in
favourable clinical outcomes when applied with caution.
In the hands of experts, proper compression leads to an
immediate improvement of pain and oedema.
Oedema
The most effective treatment to reduce oedema in
mobile patients is compression, which is also true for
patients with compensated cardiac oedema and in
patients with concomitant arterial occlusive disease in
which positive effects of compression on oedema may
be expected, as long as the external compression pres-
sure does not exceed the perfusion pressure.60 The use
of compression to treat oedema must be carefully con-
sidered in patients with heart failure, diabetes, mixed
pathology CVI or lymphoedema and/or PAOD and
after arterial bypass surgery or stenting.
Oedema in heart failure
In patients with compensated heart failure (NYHA I
and II) and venous or lymphatic oedema, compression
of both legs may lead to a short asymptomatic increase
in cardiac preload. In those patients, mild compression
should start in the lower legs before it may be extended
to the thigh region.51–53,55
Oedema in patients with diabetes
The efficacy and safety of mild compression with ‘dia-
betic socks’ (18–25mmHg) in patients with diabetes
and mild-to-moderate lower-extremity oedema were
demonstrated in a pilot study and in an RCT.72,73
Oedema and/or venous ulcers in mixed pathology
CVI or lymphoedema and/or PAOD
Compression does not always reduce arterial inflow, as
several experiments have demonstrated that the use of
compression can even lead to an increased arterial flow
in healthy individuals.74–76 Because arterial occlusive
disease is a frequent condition, especially in older age
groups, this applies particularly to patients with venous
and lymphatic diseases. In a population of 1416
patients with VLUs, 16% had concomitant arterial
occlusive disease, 2% had critical ischaemia and 14%
had an ABPI between 0.5 and 0.85.77 Critical ischae-
mia, characterised by ABPI< 0.6 or absolute perfusion
pressure values of 50mmHg, is a strict contraindica-
tion to compression therapy with MCS. However, less
severe cases, with higher perfusion pressure values,
which are far more frequent, have been shown to ben-
efit from compression therapy; this was exemplified by
a study where inelastic bandages applied with a pres-
sure not exceeding 40mmHg were able to increase local
arterial perfusion and to improve the venous pumping
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function in patients with mixed, arterial-VLU and an
ABPI> 0.5.1
Oedema after leg vein harvesting in bypass surgery
The results of several studies have demonstrated a ben-
eficial postoperative effect of mild compression follow-
ing harvest of leg veins for bypass graft surgery.78–81
Post-reconstructive oedema is very common after
revascularisation and also occurs after bypass surgery.
A prospective RCT involving patients with peripheral
arterial disease treated with autologous femoro-
popliteal bypass reconstruction demonstrated superior
oedema reduction with 15–21mmHg compression
stockings compared with IPC treatment.82
Oedema and/or venous ulcers in patients after
arterial bypass surgery or stenting
Oedema or venous ulcerations may occur or persist
after arterial bypass surgery or arterial stenting.
Inflammatory diseases and infections
Erysipelas and vasculitis
Dermatolymphangioadenitis (DLA) is described as
local tenderness and erythema, with possible systemic
symptoms, including fever and chills, related to infec-
tion and the obstruction of the lymphatic system out-
flow.83 Erysipelas and cellulitis were considered
contraindications to compression therapy due to the
risk of MC-facilitated transfer of bacteria into the cir-
culation. However, MC and concomitant antibiotics
treatment may deliver synergistic effects by reducing
local skin inflammation, improving lymphatic outflow
and decreasing local swelling-related symptoms in
patients without systemic infection symptoms related
to DLA. In some centres, compression is used immedi-
ately upon resolution of the fever and systemic infec-
tion symptoms.78,84 However, compression needs to be
made comfortable if the tissues remain tender.
Despite limited evidence from RCTs, the wide use of
compression in patients with lymphoedema decreases
oedema development and infections related to swelling,
so that application of MC can potentially prevent cel-
lulitis and reduce the risk of recurrent episodes.85
Similar outcomes are expected in other swelling- and
lymphoedema-related skin infections, such as erysipe-
las. Erysipelas, as well as its recurrence with each infec-
tion, further impairs the lymphatic system, exposing
the affected region to additional infectious episodes.
MC in combination with prolonged use of antibiotics
has been proposed by some researchers,83,86,87 and may
decrease the recurrence and flare-up of infections, and
thereby break the cycle. Based on experts’ experience,
MC therapy has a potentially positive influence on the
successful recovery of patients with pre-existing local
skin inflammation and frequent bacterial infections.
Leucocytoclastic vasculitis
The local anti-inflammatory effect of compression may
also improve skin changes, in addition to systemic
anti-inflammatory treatment.68,88, Compression in this
indication is widely used but prospective comparative
studies are missing.69
Recommendation 19. We suggest additional compression,
in purpura due to leucocytoclastic vasculitis and in leg
erysipelas or cellulitis, to reduce inflammation, pain and
oedema.
In infectious inflammation, we suggest compression
only in combination with antibacterial treatment.
Recommendation 20. Special precautions have to be taken
if MC treatment is considered in patients with ‘borderline
indications’. Treatment decisions should be taken on a
case-by-case basis and under consideration of a careful
benefit–risk assessment. In case of a favourable assess-
ment, we suggest the use of low-pressure compression,
the use of modified-compression strategies (compression
materials) and the use of padding to reduce pressure
peaks.
Contraindications for MC treatment
Based on the sections above and the literature review,
only a few contraindications for MC remain. These
include severe PAOD, compression of epifascial arteri-
al bypasses, severe cardiac insufficiency and true allergy
to compression material.
Recommendation 21
We recommend considering the following contraindica-
tions for sustained compression with TPS, ACW MCS
and elastic CB:
• In patients with severe PAOD with any of the
following: ABPI <0.6; ankle pressure <60mmHg;
toe pressure <30mmHg; transcutaneous oxygen
pressure< 20mmHg.
• Suspected compression of an existing epifascial arte-
rial bypass
• Severe cardiac insufficiency (NYHA IV)
• Routine application of MC in NYHA III without
strict indication, and clinical and haemodynamic
monitoring
• Confirmed allergy to compression material
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• Severe diabetic neuropathy with sensory loss or micro-
angiopathy with the risk of skin necrosis (this may not
apply to inelastic compression exerting low levels of sus-
tained compression pressure (modified compression)).
Conclusions
Severe adverse events due to compression treatment,
such as skin necrosis, nerve damage or thromboembol-
ic events are rarely encountered if compression is cor-
rectly used and contraindications are considered.
Discomfort, dry skin and itching are the most frequent-
ly reported adverse events related to compression use.
To prevent skin irritations in patients with sensitive
skin, we propose the use of applicable skin care.
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